TSX •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/05/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeTSX
Market Capitalization15.72 mln
Float104 mln
Earnings Date08/12/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.39
Borderline
Relative Strength
7
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-104
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Avicanna is a Canadian biopharmaceutical company focused on developing and selling cannabis-based products for consumer, medical, and pharmaceutical use across Canada and global markets. Its product range spans topical creams, oral drops, and transdermal formats sold under the RHO Phyto brand, alongside targeted treatments for conditions such as chronic pain, skin disorders, and epilepsy. The company also grows and supplies raw cannabinoid ingredients under the Aureus Santa Marta brand and runs MyMedi.ca, a bilingual online platform where patients receive pharmacist support and access to a broad selection of medical cannabis products. Founded in 2016 and based in Toronto, Avicanna works with private and public insurers to support patient reimbursement and partners with a European pharmaceutical firm to advance its proprietary drug delivery technology.